연구성과로 돌아가기
2024 연구성과별 연구자 정보 (1629 / 2344)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Kim, Insu | Kim, I | 1 | Dong A Univ, Coll Med, Dept Internal Med, Busan, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Choi, Sun Ha | Choi, SH | 2 | Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Lee, Shin Yup | Lee, SY | 3 | Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Yoo, Seung Soo | Yoo, SS | 4 | Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Park, Ji Eun | Park, JE | 5 | Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Shin, Kyeong-Cheol | Shin, KC | 6 | Yeungnam Univ, Coll Med, Dept Internal Med, Daegu, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Jang, Jong Geol | Jang, JG | 7 | Yeungnam Univ, Coll Med, Dept Internal Med, Daegu, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Hong, Kyung Soo | Hong, KS | 8 | Yeungnam Univ, Coll Med, Dept Internal Med, Daegu, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Kwon, Yong Shik | Kwon, YS | 9 | Keimyung Univ, Sch Med, Dept Internal Med, Busan, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Park, Sun Hyo | Park, SH | 10 | Keimyung Univ, Sch Med, Dept Internal Med, Busan, South Korea | JVN-6216-2024 | Park, Sun Hyo | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Choi, Keum-Ju | Choi, KJ | 11 | Daegu Catholic Univ, Coll Med, Dept Internal Med, Daegu, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Jung, Chi Young | Jung, CY | 12 | Daegu Catholic Univ, Coll Med, Dept Internal Med, Daegu, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Kim, Mi-Hyun | Kim, MH | 13 | Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Sch Med, 179 Gudeok Ro, Busan 49241, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Kim, Soo Han | Kim, SH | 14 | Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Sch Med, 179 Gudeok Ro, Busan 49241, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; | |||||
| PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC | Seol, Hee Yun | Seol, HY | 15 | Pusan Natl Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med,Yangsan Hosp, Yangsan, South Korea | ejspulm@pusan.ac.kr;fireajh@gmail.com; |
페이지 이동: